Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

al uses of such tool. The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2013. Halozyme does not undertake to update these forward-looking statements.

References
1. American Cancer Society, Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
2. Pancreatic Cancer, American Cancer Society, http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics  Accessed April 18, 2013

 

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill+Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Vycom announced ... CA, which specializes in chemical process equipment, has selected ... State University’s Facility for Rare Isotope Beams (FRIB). ... precision cleaning line made with Vycom’s Flametec PVC-C and ... are the essential parts of FRIB’s linear accelerator (known ...
(Date:8/26/2014)... 2014  Guardant Health, a healthcare company focused ... products, has been recognized today by the World ... . As an innovator in non-invasive, tumor profiling, ... a wide variety of industries and regions to ... ® , Guardant Health,s first commercially available product, ...
(Date:8/26/2014)... 26, 2014 After searching for ... research facilities , the University of Kansas Medical ... have chosen iLab Solutions' web-based core facility management ... , "We are very pleased that the ... Center signed on with us,” stated Heather Lorenz, ...
Breaking Biology Technology:ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 3
... Company also Initiates the Phase 2b ASTUTE Clinical Trial ... Therapeutics, Inc., a privately held biopharmaceutical company, announced that ... the treatment of patients with low-grade hepatic encephalopathy was ... the European Association for the Study of Liver Disease ...
... palliation as an acceptable primary endpoint, ... WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... has reached an agreement with the U.S. Food and ... Phase 3 registration trial of OGX-011, its lead product ...
... compliance and persistence with chronic medications. Prescription refills increase up ... free service offers coaching, reminders and pharmacist support to alleviate ... - prescribed medication. , ... ...
Cached Biology Technology:Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6New Pleio Medication Adherence Service Increases Prescription Refills Up To 53% 2
(Date:8/26/2014)... in St. Louis have developed algorithms to identify weak ... or breaking. The technology, which needs to be refined ... help pinpoint minor strains and tiny injuries in the ... research is available online Aug. 27 in the ... research at the nexus of the physical and life ...
(Date:8/26/2014)... a pen a New Zealand endemic tree has for the ... group of ,weedy, Australian shrubs and small trees. A New ... surprises and discover astonishing cryptic diversity behind what was long ... the open access journal PhytoKeys . , ... was one of the many discoveries made in the north-western ...
(Date:8/26/2014)... -- Unregulated trash burning around the globe is pumping ... official records. A new study led by the National ... percent of the world,s garbage is burned in such ... human health and climate change. , The new study ... of pollutants such as particulates, carbon monoxide, and mercury ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3
... Fifty-nine leading life scientists from Europe and around the ... Organization (EMBO) for their proven excellence in research. Fifty-one ... Europe and neighbouring countries, while eight equally respected scientists ... as Associate Members, bringing the current membership total to ...
... herbicide that is effective at killing broadleaf weeds in ... Illinois and other Midwestern states, may finally have a ... developed a new grape called Improved Chancellor which is ... 1946, 2,4-Dichlorophenoxyacetic or 2, 4-D was introduced. It was ...
... is available in Spanish . An ... the Institute for Research in Biomedicine (IRB Barcelona) and ... (ICIQ, Tarragona), have discovered a substance with the capacity ... certain mutations that promote the appearance of cancer. Giralt, ...
Cached Biology News:EMBO honors 59 leading life scientists 2Herbicide-resistant grape could revitalize Midwest wine industry 2Herbicide-resistant grape could revitalize Midwest wine industry 3Design of a compound that stabilizes the main natural suppressor of tumors 2
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Test Plate consists of an anodized aluminum ... Organic Fluorescent Compounds embedded in polymerized matrix. ... BioTeks FLx800 and Synergy Multi-Detection Readers. This ... compliance while reducing the need for tedious ...
Biology Products: